In one study, it was found that the stem-like cells in chronic myeloid leukaemia cell lines are relatively resistant to imatinib, a tyrosine kinase inhibitor targeting the oncogenic fusion protein BCR–ABL51. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.